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Ocular Cancer
Oinical Trials
11-E LNIVERSITY(x;TIM5 Protocols focus on
MDAN)ERSON the detection and
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CASE REPORT:
Ovarian Cancer
A new series follows
individual patients
through treatments
outlined in Compass.

@mpass 6
Quarterly S141Plement
Clinical guidelines
for the treatment
of ovarian cancer
are featured in
the Compass insert

Assessing lung
Cancer Risk
New DNA microarray
technology could
speed up genetic
screening.

MDAnderson
Newly Organized Ophthalmology
Sedion Expands Treatment
of Ocular Malignandes
by Kerry l. Wright

itaEsmaeli, M.D.,
walks down a long
hallway at The
University of Texas
M. D. Anderson Cancer Center
and into one of the three rooms
that house the institution's
ophthalmology clinic. Several
large cardboard boxes lie on
the floor, holding inside them
a brand new ophthalmic ultrasound machine, newly arrived
and ready to be set up for a
demonstration the next day.

B

Along with the ultrasound come
new possibilities for the diagnosis of
intraocular tumors and the promise
of future expansion as the fledgling
clinic settles into a permanent home.
'The goal-the vision-is to have
this truly be a regional, and possibly a
national, ocular oncology unit where
we treat primary intraocular and

ophthalmologist Bita Esmaeli, M.D., (right) an assi.stant professor in the Department
of Plastic Surgery, conducts an ocular examination in the ophthalmology dinic.
Dr. Esmaeli directs the Qphthalmofogy Service, which prooides treatment for ocular
malignancies and other cancer- and treatment-related eye conditions.

periocular tumors," said Dr. Esmaeli,
an assistant professor in the Section
of Ophthalmology, Department of
Plastic Surgery and director of the
Ophthalmology Service. ''We have
all the components to be that"

Establishing the Ophthalmology Service
Physicians in the ophthalmology
clinic currently treat intraocular,
periocular, and conjunctival malignancies, as well as orbital cancers,
(Continued on next page)

Treatment and Support of Ocular Malignandes
(Continued from page 1J
such as lymphomas, and paranasal
sinus tumors. Patients are al o een
for diagnosis and treatment o f eye
conditions that resull from nonocular can cers.
Dr. Esmaeli, an ophthalmologist
who p ecializes in ophthalmic p lastic
and reconstructive urgery, came to
M. D. Anderson only a year a nd a
half ago as parl of an experim e nt
LO see if a ucce fut, free-standing
Section of Ophthalmology could be
created. Since the o phtha lmo logy
clinic o pe ned in 10,·ember 1998
under the auspice~ of the Department o f Plastic Surgery, the number
of patien ts who arc treated al the
clinic each month has increased
by more than 400%.
T h e number of full-time faculty
in the Section o f Ophlhalmo logy i
expected to at lea.,t d ou ble by the end
o f 2000; a pediatric o phthalmologist
and an ocular o ncologi t arc among
those joining the team. Many pa rttime and volunteer faculty fro m various ub pecialtic of o phthalmolog)'
are also involved in treating patients,
and close collabortttions exist with
the De partment of Ophthalmology
at Baylor College of lcdicine and
with pediatric o ncologi ts, racli.nion
o nco logists, head and n eck o n cologi ts, and plastic <;u1geons at M . 0.
Anderson.

Multidlsdplinary approach
to treating retinoblastoma
Amo ng the clin ic'-; main prioritie
i the treatme nt of retinoblastoma,
the m o t comm o n intraocular tumor
in chi ldren. Retinobla.sto ma occurs at
an e timated rate o f I case per 18,000
to 30,000 birth and is usua lly diagno ed before a child 's econd birthda)'. Approximatd, 40% of patients
with retinobla.<;to ma h;we inlwrited a
d efect in their rcti noblastoma tumor
uppressor gen e, ,o the}' are a l,o a t
increased risk for no nocular tumors
througho ut their liH·\. Rc tino blas tomas a rc known to mctastasi,e quick! ,
o a ppropriate and timel)' treatment
o f primarv tumor, i, c cntial.
..One o f the wa,, to ucce-,_,fully
treat retinoblastoma is to combine
2 / MO

ndcrson O,woLog

who works closely with Or.
ch emotherapy, radia"In both
Esmaeli to treat patients
tion the rapy,
with uveal melanoma.
and loca l urgical
retinoblastoma
"Standa rd radiation
measures uch as
and uveal
u ·e e lectrons," said Dr.
cryothe ra py or laser
Garden, "either by
treatment," said Dr.
melanoma,
themsel\'es or to create
Esmaeli. For large,
therapeutic photom,. The
unilateral tumors,
the
trend
is
theoretical aclvantag<.· o{
complete removal of
proto n s i based on tlwi,
the affected eye may
to preserve the
phy ical properties, no t
be the prefe rred
the
ir biological propt·•·
method of treatment.
eye whenever
tics." Prowm confm m
For bilate ral retinowdl to nan ow, cxan
bla to ma tumors,
possible:·
beams and ddhcr 111m1
howeve r, the more
of the ir e nergy at the encl of tlw11
di cased C)'C i n o rmally e nuclcatccl,
range. These c haract(·1 i,tk, mak1· it
and the o ther eye is preserved.
po siblc 10 u c.tt tlw tumm \\l11k
Recent tre nds in the managcmcm of
,;paring
a ,;ignificant po, tion of
rctinoblai;to ma include the me of a
adjacent
normal ti ,u(·, in tlw t , ,.
comb ina tion o f chemotherapy and
and , in many c:ascs, 'i,l\'i11g tlw
conservative eye-preserving surgical
patient\ vhion.
techniques, c,en in unila tcrttl ca,es.
·Anotlw1 ach~,rn1..,gc.· of 1lw 111111 1
~, n both retinoblastoma and ll\eal
beam b tJrnt )OIi don't haw to ho,,,
melano m a, the most common type
ofintraocular tumor in adulL'l, the
1ali,c the patit·n1 fo , \t'H't ,1I dm,
trend ii; to preo;en e tht: e)'C wlwne,cr while a rnclic>.1cti,e pl,1C1u1· "011
<;aid Dr. fam.wh. I. D. \ ndt·r..1111 t
possible," said Or. Esmacli.
expected 10 romplew ton,trut '""
Proton beam therapy
o f a proton lwam 1rca1nwnt u ·11111
for uveal melanomas
within th<.• 1wxt H'a1, mal..111g i1 1111
Radiotherttp y o fte n play a pi,otal
the third ct•ntcr in tht' rou1\11 , to
role in the trcatrncnL o f uveal melat he technique for Lhc t1t•,11mt·111 11
noma, a dii;casc that attacks the uvcal ocu lar tumo1,.
tract o f the ere ( mo'lt often the
choroid}. Except for cnuclcatio n in
Using chemo-ffl1bollzation
the case of large tumors, plaque
to fight liver metastases
radiotherap is currently the stanpproxiniatd} 309f to IO', of
dard treatment for meal melanoma.
patients with ll\Cal mt: lanom,11·\1
For plaque radiotherap,, a radiatio n
all\ cle\'elop di tant nwt.1,1.1,1·,. 111
o ncologi,t, r.1dia tion ph , icist, and
often to the li\cr, <;aid Dr. hm.11 lr
o phthalmo logi t desig n a gold-plated
'ltcmic cht.·mothcrnp, tM·cl 101
meta l plaque with rc1dioactive i;eecb
c: utancou, melanoma h ,1'> not p1 o
placed imicle. The plaque i, se\, n
tx.-ncficial in thi, patit·nt popul.1111
o n to the t.·ye for three to e\'en ch\\ s.
and according to Agop \ lkcl1l..1.1
de pending on the radiation clos.1ge.
~I.I)., a proft-.,-,or in tlw lkpa, t111t
then remm ed .
o f Mdanom,1 S,,rcoma \kcli< .1
An alternathe to radioacti,c p laque
Onc:olog\, <hemo-embol11.1tion ,,
thcrapy---ancl a potcntiall · more
· ttw best th(·1,,p, for p.ll1t·nh \\ 11h
i.pecific method of su11,Tically applkcl
mc t,..,tatic cho1oiclal md,mom.1 ti,
radiatio n-i, proton beam therap,.
i, t'onfined to the liH·1. • Fo1 tht
'The 1..e, thing to n.•cognvc i, that
proccclurt.'. a r,1cliolog"t 111trod 1111
the eye is \Cmith·e 10 radiatio n , ,mcl
., c:,1thcte 1 into the p,tut·nt\ k mw.
high radiation d osci; 10 the entire {')'C
a, tt.•ry and ming nuoi O',(Opic"
c:an be blinding. ., said Adam . Carguidance, mmt.·, it up 1lw .,on.,
d en, M.0 ., an a.~iate profC'>SOr in the ,met into tht· lwpatic .u lt.'n th,tt
Department of Radiation Oncol<>f.."
, upplie blood to th e tumor in the

PROTOCOLS-- - Studies Aim to Detect and Treat Ocular Malignancies
Clinical trials in progress at The University of Texas M. 0. Anderson Cancer Center
include the following for patients with
ocular melanomas.
• A search for serologic markers for
metastatic melanoma of the uveal tract
(ID00-040). Physician: Bita Esmaeli,

M.O.
This study aims to identify serologic
markers for earlier detection of metastasis in uveal melanoma. The serum of
patients with end-stage melanoma and
healthy control subjects will be analyzed
at the molecular and protein levels.
Participants must be older than 18 years
and have metastatic uveal melanoma as
proven by histological or imaging
studies.
• Sentinel lymph node localization and
biopsy for conjunctiva! melanomas: A
pilot study (GSP00-106). Physician: Bita
Esmaeli. M.0.
This study is designed for patients at
least 18 years old who have histologically documented malignant melanoma
of the conjunctiva (greater than 1 mm in
thickness) but have no clinical evidence

liH·1. Starch parrid cs and the chc1110the1apc.·111ic agen t ci,platin are I hen
.ulmini,t(•rc.·d frnm a ,Hinge through
the ca1lwtt·1. ·1 lw ,tarch panic:lcl!
f,111,t· 11,tmic: nt gelling of the blood,
\,hi< h 1101 onh deprin·, 1lw tumor
of m ..,gen ancl nutrition but .1l'i<>
1110 tw,t·, co111ac I tinw b(·rwecn the
ci,pl,,tin and the 1umo1 c<.'lls.
"' I he (<>mbination of th<·,<.' efft·c ,.,
1 t·,uh, in lll' <TO'>i, of the tumor cclh.
,, hic"h liqm·f, and .u-e ,lowly ab,oilwcl ,lllcl c karecl h, the boch, ~
D1. lkclil..ian \aicl. Nt·w chemothcrapt•ut ic· agtn l\ .u c al-.o bl'i ng off<.·n·d
.1, 111H·,1ig,1tional thnapic.·, to treat
ll\ t·al nw l,1noma nw1a,1,Hic to the
lht·1 and othc.·1 organ,.

Supportive care for patients
with oa,far complications
fhc.· o phthalmolog\ clinic ill aim
a full-time.• ,uppon n·n1t•r for patient!>
,, ith ,t wide range of ocular problem,.

of regional nodal disease or systemic
metastasis by chest x-ray, liver function
tests, and head and neck computed
tomography. Patients must be able to
undergo outpatient surgery under
general anesthesia and return to M. D.
Anderson approximately every three
months for follow-up. Women who are
pregnant, nursing, or not using reliable
birth control measures may not participate.
• Phase II evaluation of temozolomide in
metastatic choroidal melanoma (DM99352). Physician: Agop Y. Bedikian, M.O.
Participants must have metastatic
choroidal melanoma with bidimen·
sionally measurable disease and a life
expectancy of at least eight weeks.
Patients may not have undergone
chemotherapy with a dacarbazinecontaining regimen but may have
received chemotherapy or radiation
therapy three or more weeks prior to
study entry if fully recovered from
treatment. Patients with uncontrolled
central nervous system involvement
or a serious intercurrent illness cannot
enroll.

Along with rad iation oncologi,t-'>, the
ophthalmologi,u, in the clinic 1rca1
ocuhu meta.'>ta,cs in patient-'> with
brca-.1 and lung cancer and offl'r
1;crccning for rl'ti nal and corneal
,ick effects of chc mo1hnap<'11tic
drug,. In addition, one of thc: largc-,1
populatiom requiring ophthalmologic a,,<''>sment are patient, who
have 11ndergo11<.' bone.· marrow
u.111,plantation. Ocular graft-, er,u..ho,t cfo,<.·a,<' ancl po,terior ,ubca1N1lar ca1ar.1ct, an.· fa irl) common
in patienL, who havl' Imel a bone
marrow 1r.1n,plant.
·we lll'l' quite.· a few caM·, of ,e,cn·
intmocular infection. including
encloph thalmitis. in our population
of im11111nocompromi,cd patien b."
Dr. Esmaeli •,aid.
The operating morn ,u \I. D.
,\nclt.·r!>Oll rccenth acquired cquipnwnt that allow, oph th almic ,urgeon-'> to pt•rform pron•clun•~ MKh

• A randomized, parallel design, phase II
study of paclitaxel administered weekly
with or without the matrix metalloprotease inhibitor prinomastat (AG3340022) in patients with metastatic melanoma (1000-171 ). Physician: Agop Y.
Bedikian, M.O.
Participants must have metastatic
choroidal melanoma with bidimensionally measurable disease and a life
expectancy of at least eight weeks.
Patients with cutaneous melanoma are
eligible if they have had prior dacarbazine therapy; patients with ocular
melanoma are eligible with or without
prior chemotherapy. Patients with
uncontrolled central nervous system
involvement or a serious intercurrent
illness cannot enroll. •
FOR MORE INFORMATION about tlu e clinical
trials, phyficitms ()T patients may r,all the
M . D. A11d,rson lnfonnation Lint. Those
within lilt Uniltd Stales should rail (800)
392-161I; thou in Il<nt5lon ()T outsidt
th, U11it,d States rhouul rail (713) 7926 / 61. Visillht M. D. Anderson umr,r
Cenll'T diniral trials ¾~b site at htip://
r1.11.11w. rliniralJrials.orgfor a broruln Ii ding
of lrn1tmmt rP~ttlrrll /m>lorol,.

a, \itrcoretinal , urgcry (for

l h t·

d iagnmi, of i11traocula1 l)tnphoma
and inf cctiou-. cndoph th,\lmi1is)
and cataract surg('1 \ .
··one of our immccliaw future
goal., i, to reach out 10 the ophthalmologi\h in the comm11nit} and
nationwide and make them aware of
tht late~t trc.·atmenh a\'ailablc at
~t. D.. \ nclcr,on. \\'<.· hope to be able
10 s<.·t up an tH· cancer regi try in
tlw m·ar future that will li kely help
ll\ iden1ih tn·nch in natural histor"
ancl llT,Hmc.·111 options for ome of
the mort· rare t~e malignan cic~."
said Dr. 1-\ maeli. •

FoR MORE INFORMATION, rontart Dr.
/,;.\ llltlf/, at ( 71 J) 79-1- 12-17 or su

thr
Sertum of Ophtlwlmology \\rb silt
at hll/>://www/ DEPM1T,\ll~\ TS/
pl1L\lirj.,,p1,1Im/. J,t,11.

Clinical Practice Guidelines

Ovarian Cancer
This case report of a patient with stage IV ovarian cancer is the
first in a series of individual treatment summaries that correspond to and serve to illustrate the Clinical Practice Guidelines
found in Compass.

A

s in most cases of ovarian cancer,
tumor was discovered in an advan • I • . I ' • ein this instance during a workup for pleural effusion
prompted by a chest x-ray taken of the 75-year-old woman
during outpatient evaluation for indigestion. Thoracentesis
revealed numerous papillary clusters of malignant cells with
psammoma bodies in the fluid and strong immunocytochemical
activity to CA 125 (a tumor marker for ovarian cancer).
In light of these findings,
nderwent computed
tomography (CT) of the abdomen and pelvis that revealed an
abnormal soft tissue density in the central pelvis, bilateral pleural
effusions with pelvic ascites, and a large cyst on the right kidney.
Subsequent ultrasonography of the abdomen showed a complex
pelvic mass. Mrs. Newman was referred to The University of
Texas M. D. Anderson Cancer Center for staging and treatment.
Physicians at M. D. Anderson discussed two treatment options
with
initial surgery followed by
chemo erapy an c emo erapy allowed by exp~
~
Yand tumor reduction surgery. Becaus. . . . lllllllllllll"as in moderately good health and because initial
surgery would allow for a definitive tissue diagnosis, it was
agreed to first treat her with surgery, aimed at both confirming
her disease stage and reducing the size of her tumor. Subsequent pathologic examination indicated that she had stage IV
ovarian cancer, the most serious stage of the disease.
Because of the advanced stage of her cancer, surgery alone was
not sufficient treatment, and doctors initiated a chemotherapy
regimen of paclitaxel and cisplatin. She received six cycles of
chemotherapy and, as in most patients, her disease responded
well. After six months of treatment. her CA 125 level was 38
(normal < 35 units/ml), down from a preoperative level of 3,071.
ad no evidence of disease during chemotherapy,
ua
e sixth cycle, a CT scan revealed a 2-cm peritoneal
mass. Her CA 125 level had declined on paclitaxel/cisplatin
chemotherapy, but
till had evidence of persistent
cancer and required further chemotherapy. Unfortunately,
doctors had to choose a new agent because, though successful,
paclitaxel/cisplatm therapy had caused substantial side effects:
hearing loss, lower extremity paresthesia, and hypomagnesemia. Physicians changed her regimen to carboplatin.
After six cycles of carboplatin treatmentxperienced a period of calm, with a falling CA 125 level and no sign
of recurrence. She lived much of the year without chemotherapy, showing no evidence of disease and receiving medical
care only for pneumonia.
4 I 11D Amfrr1w11 Ont·oLog

CASE REPORT
Late in the year, a CT scan and subsequent biopsy revealed
metastatrc disease adjacent to an abdominal muscle, and
doctors restarted chemotherapy with carboplatin. Because a
significant period of time had elapsed since - was last treated with the drug, physicians ha~
believe carboplatin would still be effective. This time, however, the drug was not as effective, and she experienced a
number of side effects. In addition, after four cycles of
carboplatin, a rise in her CA 125 level was noted, and doctors
discontinued the treatment.
Physicians at M. D. Anderson continued to search for a drug
or drug combination to which ~
ncer would
consistently respond without ~
ide effects.
Topotecan treatment followed carboplatin therapy. After 10
cycles of topotecan, chemotherapy was postponed because
of bronchitis and neutropenic fever. Topotecan treatment was
then resumed with granulocyte colony-stimulating factor (GCSF) support (aimed at decreasing the incidence of infeclion)
for a total of 23 cycles. Side effects of topotecan were
minimal and included fatigue and a recurring rash but G-CSF
caused significant bone pain
esponded to
topotecan for approximately a year and a half. but her CA 125
level eventually began to rise once again
Noting the rise in her CA 125 level and discovering furth r
metastatic disease (this time in the left axillary node). M IJ
Anderson physicians changed her treatment from topotr
to gemcitabine. This drug therapy lasted for eight month
d
caused her CA 125 level to decline. Chronic bronchitis a
chronic cough often delayed chemotherapy and were tr
with steroids, antibiotics, and inhalants. Though her CA
level declined with gemcitabine treatment, doctors disc
ued it, suspecting a connection between the treatment a
ulmonary problems.
Hormona l therapy with tamox1fen was then attempted
Shortly after. metastatic disease was detected in her le
breast. and tamoxifen use was discontinued in favor of
liposomal doxorubicin (Doxil).
Now 80 years old,
mains on Ooxil the
She continues to have numbness in her lower extr mt
respiratory difficulties, and occasional problems w h
ambulation. Her chest x-rays have shown stable d ea
d
her CA 125 level was most recently calculated at 1-1 s
s
number Is far from normal, but her disease's respo 1s
treatment has been, in general, remarkable. Pat1enb v
stage IV ovarian cancer have a median survival durat1C; '
approx· t I tw
sand a five-year survival rate of o
to 2%.
as thus far lived five years from
time of
Written by: Rebecca Gershenson Sm ith
•Name has been changed to protect the 1dent,ty of the patient
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About These Clinical
Practice Guidelines
g1tideli11e5 ITW) <IHiJt in the
diag1101/ir evaluation of patients with
rli11iml \Jmptom~ or po1itive srree11i11g
tl'5f\ (if wch tl'sling pxisls). The cli11irim1 is l'XjJPclnl lo IHI' irulP/Jnulmt
mediml judgmml in the conlPxl of
individual cliniml rircu mst<WCI'\ to
dPIPrminP any /mlienl \ care.
M . /). AndPnrm Cancer Cmler'.s
Pmclire (;uidPline1 are co11ti1111all)'
updatPd (15 nl'W information becomes
availabll' and arl' being expandPd lo
include /Ill' mlirl' ~J,ec/rum ofm11rer
mrmagemmt. .\'ew guidPLinP1 for
\creming mu/ diagno.si.s are currently
11nder develo/mteul. Acce.s5 the 1110.st
currml vt>rsiou ofall ,\ /. D. A 11derso11
Pmctice G11idPLine1from /\I. D.
A ndm.011 's / Jome Pagr al hllp:/ I
www.mdmu/Pn011.org.
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Continuing Medical Education:
An expanded version of these
materials with CME category l
credit is available on the Internet.
Choose ' Practice Guidelines· from
M. 0. Anderson's Home Page at
http://www.mdanderson.org
- -'------- -
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Ovarian Cancer
Scope of This Guideline
This guideline addresses lhe
evaluation and treatme nt of
epithe lial 0\-arian cancer, which
accounlS for approximately 90%
of ovaria n n eoplasm s.

Synopsis & Highlights
O verview
Two hallmarks of this le lhal
disease are that it is insidious,
o ften producing no alarming
symptoms even in advanced
stages, and th at it is by nature a
disease that spread s readily
throughout the pe ritoneal cavity
on ,·isccral and parietal surfaces
and in abdominal fluid s (asci1es) .
There is currently no effective screening measure for
ovarian can cer. Early-stage
disease is most oflen discovered
as a pelvic mass during a rou tin e
examination. Patients may be
entirely asymptomatic o r may

have only vague or seem ingly m inor
symptoms: tumors m a)' grow to a
rather large size before produci ng
symploms su ch as u rin ary freq u en cy
or rectal p ressure; in more advan ced disease, patients m ay com p lain of abdominal b loaling o r
d islention related to ascites or o f
respiratory sym ploms associa ted
with p leural effusion. O ccasio n a lly,
even in advanced d isease, ovaries
may be normal in size upo n examination .
The d efi ni tive d iagnosis o f
ovarian cancer is m ade by hiswlogic
stud y of tissues and flu id s re m oved
durin g the initial surgery, whic h is a
compreh ensive staging explorato ry
laparotomy. This surgery is a critical
event in the m an agem e nt of this
d isease, as a ll trcalm e n t decisions,
and lh erefore o utcomes, a re based
upon accurate staging. Accord ing to
NIH recommen dalion s, a woman
with suspected ovaria n can cer
should b e g iven the opportun ity to
have the laparotomy performed by
a gynecologic oncologist.
Ch emotherapy is the otJ1er mainstay of trcaLmen t and is indicated as a
primary postoperative treatment in all
situations except for very early, welld i1ferenliated, and limited d isease
(Co11 ti111.1Pd on next page)

(Continued from previous page)

(stage IA) . Chemotherapy a lso p lays
a major role in the management of
recurrent or progressing disease.
Second-look surgery for the
purpose of monitoring disease is not
considered necessary unless it will
change disease management, so it is
not routinely recommended outside of
select clinical trials or unusual clinical
presentations. However, for patients
with recurrent disease, a second
laparotomy may be indicated for
de bulking (secondary cytoreduction).
At all points in the guideline
where clin ical trials are listed as an
option, our authors recommend them
as the best choice.

Primary Treatment
Pelvic mass at clinical presmtation

Patients who present with suspected ovarian cancer manifested as a
pelvic mass should undergo a thorough preoperative physical examination and m edical history. Because

surgery is anticipated, the evaluation
usually also includes a chest x-ray, an
ECG, and any additional preoperative
workup indicated for individual
patients. Imaging studies such as
abdominal CT scans may help locate
a nd assess the extent of disease, but
extensive imaging is not necessary,
particularly if it delays definitive
management. For the same reason,
no preoperative biopsies to obtain
material for cytologic or histologic
evaluation are recommended, nor is
paracentesis for abdominal ascites or
effusions, as material for pathological
examination will be obtained at the
time of surgery.
An exploratory laparotomy for
comprehensive staging and cytoreduction is the initial intervention,
except in patients who are medically
unstable. The latter patients may
benefit from chemotherapy first.
According to Dr. Gershenson, the
initial surgery should be done
through a vertical midline incision

to provide an adequate field for
biopsy and resection. Laparoscopy is
not appropriate or adequate for the
initial surgery. The procedure should
include:
• evacuation of ascites if present, with
submission of samples for cytologic
evaluation
• cytologic washings of the pelvis,
bilateral paracolic gutters, and
subdiaphragmatic areas performed
p rior to manipulation of intraperitoneal contents
• careful systematic inspection and
palpation of the entire peritoneal
cavity with excision or biopsy of
any suspicious area
• assessment of both ovaries for size,
evidence of tumor involvement, or
adhesion
• removal of the primary ovarian
tumor intact
• generous random biopsies of all
peritoneal surfaces
• where gross metastatic disease is
encountered, an aggressive attempt

0

Epithelial Ovarian Cancer (1)
CLJNICAL
PRESENTATION

I

a.. I

INITIAL
EVALUATION

PRIMARY
TREATMENT

CXR
Verify most recent
mammogram
CA125
Ultrasound or
CT of abdomen
and pelvis if
suspicion of cancer
Barium enema if
clinically indicated

Appropriate surgery
. - - - ~ and staging

Diagnosis I
by previous I
surgery

I

Incomplete surgery
and/or staging:
1. Uterus not removed
2. Adnexa not
removed
3. Omentum not
removed
4. Documentation of
staging inadequate
5. Suboptimal effort

PRIMARY
ADJUVANT
THERAPY

SURVEILLANCE

►~o adjuvant

Grade 1
(Low grade)

Laparotomy/TAH/BSO with
comprehensive staging or
If stage I, grade 1 and patient
desires fertility, USO and staging
biopsies or
If stage 111or IV and medically
stable, cytoreductive surgery or
If patient unable to tolerate surgery,
consider chemotherapy.

ai. I

CXR
CA125
Ultrasound or
CT of
abdomen
and pelvis if
clinically
indicated

PATHOLOGIC
STAGE

Stage IA
or IB

therapy

K

~

Options based on
individual patient
characteristics:
1. Immediate
chemotherapy
2. Chemotherapy
followed by interval
cY1oreduction
3. Re-explore for
cytoreduction

• Paclitaxel with
cisplatin for 6
cycles or
• Paclitaxel with
carboplatin for
6 cycles or
• Single-agent
carboplatin

• Paclitaxel with
carboplatin for
Stage II, ~ 6 cycles or .
• Pachtaxel with
111 or IV
'
cisplatin for 6
cycles or
• Clinical trial if
available

sits every 3
o for 4 visits,
then every 4 mo
for 3 visits, then
every 6 mo for 6
visits
• Physical and
pelvic exam every
visit
• CA125 (if initially
elevated) every
visit
- Mg every visit (if
received .:6
cycles cisplatin)
- CT of abdomen
and pelvis or
CXR if indicated
by signs or
symptdr'ns; not
routine

I

Grade 2
or 3
(High grade)

){ ai. I

I<
J

,--

Ver:Compass/212/# 1

Epithelial Ovarian Cancer (2)

Q

- - -

CONSOLIDATION TREATMENT

I

Stage II
Stage 111
or IV

See
CONSOLIDATION
TREATMENT
on chart 2

TAH = Total abdominal hysterectomy
BSO = Bilateral salpingo-oophorectomy
USO= Unilateral salpingo-oophorectomy

Stage Ill and IV
complete remission

Treatment

~-----•►M1

.

• Observe or
• Second-look surgery (laparoscopy or laparotomy) or
• Continue paclitaxel or
• Carboplatin for 6 cycles or
• Paclitaxel and carboplatin

I

► Surveillance as for

I

111111

rreatment

I

stage I and II

• Clinical trial or

Stage Ill and IV
partial remission

~

I

I • Continue paclitaxel or
•

Carboplatin or
• Salvage chemotherapy as described in Box A or
• Hormonal therapy (tamoxifen)

RELAPSE OR PROGRESSION

.--------,

Surveillance·

, ~~
Yes

Clinical relapse ----M

Stage I and II relapse
or progression

___________________
N_o
Rising CA125 level only

Stage Ill and IV
disease progression

• Clinical trial or
• Chemotherapy/hormonal therapy or
• Initiate salvage therapy when clinical disease apparent

l

Laparotomy or cytoreductive
..- surgery followed by chemotherapy

►

I

Surveillance·

I

Individualize surveillance
as appropriate

SALVAGE
No previous
chemotherapy

• Paclitaxel and cisplatin or
• Paclitaxel and carboplatin

No response or
• Clinical trial or
progression on
_.___
• Salvage chemotherapy (not to exceed any two regimens below)
primary chemotherapy 1 - - - - - - - - - - - - - - - - - - - i ~ I
· Topotecan
• Liposomal doxorubicin
- Docetaxel
or relapse <6 mo after
• Vinorelbine
- Oral etoposide
- Gemcitabine
stopping chemotherapy
------------- Altretamine (hexamethylmelamine) or
(paclitaxel and
O f
b
d
rf
)
• Hormonal therapy (tamoxifen) {does not count as one of the two)
cisplatin-resistant)
P ions ase_ on pe ormance
_
status and primary therapy:
• Paclitaxel and platinumYes
Relapse ~ mo after
based treatment
stopping chemotherapy
• Paclitaxel
No
Surveillance pending tumor status·
• Carboplatin
• Clinical trial

r

Low-grade, focal
recurrence after long
disease-free interval

r-----------------,~1

'Refer to SURVEILLANCE on chart 1

• Secondary cytoreductive surgery or
• Consider chemotherapy or
clinical trials

Ver:Compass/'2/2112

This /m1ctice guideline was develb/1e,:l in a collahorative effqrt between the physicians and nurses at The Uni11ersity of Texas 1\4. D. Anderson Cancer Center and the
Natfonal Comprehensive Cancer Network. 171e cme deuelofnnmt team at M. D. Anderson working on this practice guideline included D1: Robert C. Bast, Jr., O,: Thomas
w: Burlie, Dr. David M. Gershenson, Dr. JohnJ. Kavanagh, and Di: Mitchell Monis.

to remove it should be made;
where removal is not possible, it
should be sampled to document
the extent of disease
• careful examination of para-aor tic
and bilateral pelvic lymph nodebearing areas, including those in
the retroperitoneum, with biopsy
or removal of suspicious nodes
• thorough documentation of the
en tire procedure
Based on intraoperative findings
and frozen section analysis, hysterectomy and bilateral salpingo-oophorectomy and omentectomy may be
performed. Conservative surgery may
be possible in patients who want to
preserve childbearing ability if they are
found to have limited and early (stage
I, grade 1) disease. Although this is not
freq uently an issue in epithelial
ovarian cancer, Dr. Morris points out
that the surgeon should always understand its importance to the patient and
stresses the need for good preoperative
cou nseling; the options and decisions
that will be made intraoperatively
should be discussed with the patient
beforehand.
Following surgery, further treatment is directed by disease stage. In
patients with low-grade (stage IA),
well-differentiated tumors limited to
the ovary and no residual disease,
surgery alone produces a long-term
survival rate of >90%. In this setting,
additional chemotherapy is not
warranted, nor has it been shown to
increase the lo ng-term survival rate.
All others should receive primary
adjuvant chemotherapy. According to
Dr. Bast, for patients with stages II-IV
disease, combination therapy with a
taxane-based agent (paclitaxel or
docetaxel) and a platinum derivative
(cisplatin or carboplatin) is standard.
For patients with low-grade, early-stage
disease (stage IB-IC), more study is
needed to determine the optimal
agent or combination of agents to use.
Currently, paclitaxel with cisplatin or
carboplatin is recommended; singleagent carboplatin is considered by
some experts to be as effective as the
combination, but this issue is quite
controversial.
The serum tumor marker CA125
is an important prognostic factor, and
its levels should be monitored prior
to therapy, after cytoreduction, and
between cycles of chemotherapy. "We
hope to see CA125 levels normalize by
the third cycle, as studies suggest that
this is associated with a better prognostic outlook," says Dr. Gershenson .
Measurement ofCA125 should be
repeated at each follow-up visit after
treatment; a progressively rising level
is strongly predictive of disease
recurrence and can precede physical
exam findings and radiographic
studies by as much as 3 months.
Ovari,an cancer diagnosed
by previous surgery

When a patient presents with
ovarian cancer diag nosed during a
previous surgical procedure, the first
challenge is to determine the adequacy of the in itial surgery with
regard to staging. Where staging is
incomplete, re-staging surgery or
chemotherapy may be recommended.

Consolidation Treatment
Following six cycles of primary
chemotherapy, patients with stage I-II
disease should receive follow-up care
as shown in the surveillance recommendations. Patients with more
advanced (stage III-IV) disease may
be considered for funher (consolidation) treatment.
■ Patients with partial remission of

disease after initial therapy are at high
risk for r elapse and should receive
additional chemotherapy, with the
choice of agent based upon earlier
responses: paclitaxel or carboplatin
are continued if response to either
was noted; carboplatin or cisplatin
may be tried if they were not previ(Continued on next page)

(Continued from previous page)
ously used. In situations where disease
is judged resistant to these first-line
agents, other drugs are used (see
Box A on guideline).
The use of hormonal therapy
(tamoxifen) in consolidation treatment is somewhat controversial: no
trials have shown it to be more
effective than chemotherapy, and
there is no evidence that it prolongs
dise ase-free survival. In the treatment
of recurrence, however, tamoxifen
may provide an alternative to more
toxic agents in certain patients,
particularly where there is indolent
disease, provided the patie nt is
carefully monitored.
■ For patients

with complete remission
of disease after initial therapy, the

decision to continue treatment is less
clear cut. The options are o bservation
alone, continued chemotherapy, and
second-look surgery. In this setting,
the evide nce is not conclusive that
continued chemotherapy is superior
to observation alone, so it is a situation in which clinical judgment must
be based on the individual patient,
and close consultation with her is
part of this decision.
Similarly, second-look surge ry is
somewhat controversial. "vVe ho nestly
don't know which of th ese options is
better," says Dr. Ge rshe nson, "because
there have bee n no prospective
randomized trials, and reu·ospective
data don't show surgery to be better,
although we know that information
obtained surgically is more accurate
than that imparted by CT scan or by
measurement of CA125 levels." At
M. D. Anderson, second-look surgery
is included in some protocols for
study purposes. "At this time we feel
it's best done in the setting of a
clinical tria l o r as part of an unusual
patient presentation where the
information is used to make treat-

ment decisions," says Dr. Morris.
"If the second look will not change
those, then it is more controversial,
particularly in cases where CA125
levels and CT scans are normal."
It should be noted, however, that
the patient's personal choice is an
important factor. "Many women feel
strongly about having the second
surgery," says Dr. Ge rshe nson. "We
don't have a pe rsonal bias either way
but try to present the patient with a
balanced view."

Management of Relapse
or Progression of Disease
Management decisions in recurrent or progressing disease are based
upon disease stage and the presence
of clinical signs. Patients with stage III disease whose CA125 levels rise
should be examined by CT scan to
confirm the presence and extent of
residual disease. For these patients,
cytoreductive surgery may be indicated and should be followed by
chemotherapy. vVhether to treat a
rising CA125 level with chemotherapy
in the absence of other evide nce of
recurrence re mains controversial.
Patients with stage III-IV disease that
relapses or progresses during chemothe rapy should be considered for
clinical trials or for chemotherapy with
another agent. vVhen relapse occurs six
months or later following the end of
treatment, there is an approximately
45% chance that disease may be
considered sensitive to the original
agent (paclitaxel, cisplatin, or
carboplatin) and will respond to it
vVhen relapse occurs in less than six
mo nths, there is red uced chance of
response to these agents (i.e., resistance
is likely), and another drug should be
tried. Of the agents listed (see Box A o n
guideline) , there are few studies or
reliable tests to he lp predict which one
will produce a response.
''In most patients (80%), disease

responds to chemotherapy initially,"
says Dr. Gershenson. 'The problem is
maintaining response, or achieving
'durable response.' The problem is
development of resistance and relapse."

Authors' Perspectives
The first surgery is the most
critical event in the course of a
patient's treatment. "One of the
major issues for us is that only a small
percentage of women have undergone cancer surgery where comprehensive staging was achieved," says Dr.
Gershe nson. H e notes that one
should always consider the possibility
of malignancy, even in young patien ts.
It is always appropriate to include a
gynecologic oncologist in consultation and surgical planning whe n
there is suspected cancer.
Ovarian cancer, though curable,
remains a lethal disease for most
women in spite of advances made in
treatment over the past few decades.
According to Dr. Morris, "In the past
20 years, the strides made in ovarian
cancer treatment have been significant
increases in life expectancy and
survival rates, along with a dramatic
reduction in the side effects of n·eatment, which has greatly enhanced
quality oflife for our patients. Our
biggest continuing challenge is that
70% of patients with ovarian cancer
present with advanced disease."
Clinical trials offer the best hope
for improving therapy, says Dr. Bast.
Wha t is badly needed, he says, are
accurate tests for predicting drug
responses that will enable clinicians
to select those drugs that are the
most appropriate agents for individual patients. There is research
under way to develop assays for
this purpose.
Fin d more information about
clinical trials and current protocols
available at M. D. Anderson at http://
www.m.danderson.mg/research/
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Virtual Health: Finding Reliable
Medical Resources on the Internet
he popularity of the
Internet has made
obtaining medical
information easier than
ever before, but it is important
to keep in mind that not all
of the information available
on the Internet is useful or
accurate.
How can you ensure that
the medical information you 're
reading about on the Internet
is reliable?

T

Ask your doctor
When in doubt, always discuss the
information you have found with a
medically trained p rofessional. Even
information from a well-respected
source should supplement, rather
than replace, the advice of your
physician.

Consider the source
If an Internet site is reputable,
it should clearly state who is responsible for the information presented.
Look to see if the person or organization in charge of the site created the
information. If not, the original
source should be documented.
I t is also h elpful to know how the
I nternet site is funded. For example,
•

M~aVosta ~ MA

@'.) Search

Recommended Cancer-Related Sites
American Cancer Society: www.cancer.org
A comprehensive site covering types of cancer, treatment options, and news articles.
cancerfacts.com: www.cancerfacts.com
Provides personalized, interactive treatment options and survival and recurrence rates
for people with cancer, news articles, and articles written by people with cancer.
CancerSource.com: www.cancersource.com
Contains general information about cancer and links to news articles.
Cancer Survivor's Network: www.cancersurvivorsnetwork.org
Covers a wide range of topics important to patients with cancer and those close to
them, including coping with fear, financial planning, and long-term effects of treatment.
Healthfinder: www.healthfinder.gov
Ageneral health site that provides a medical dictionary, a link for cancer information, and
links to on-line medical journals and health-related sites.
M. D. Anderson Cancer Center: www.mdanderson.org
Explains clinical trials, offers advice on cancer prevention, provides a glossary of terms,
and gives information about M. D. Anderson's services and activities.
National Cancer Institute: www.nci.nih.gov
A comprehensive site with information on types of cancer, clinical trials, statistics, etc.

~Go
»

an Internet site funded by a drug
company could potentially create
a bias in the site's information.

Is the information supported?
A good Internet site should clearly
differentiate between facts and
opinions. Material presented as fact
should be referenced, i.e., should
refer the reader to the results of a
study, to a reference in a medical
journal, or to specific Internet sites.

How isthe information selected?
An Internet site that selects the
information presented via consultation with medically qualified individuals or an editorial board is
more reliable than other sites.

Is the information current?
A useful Internet site shou ld post
the date of the most recent review or
update of its material. It is important
that the person or organization
running the site reviews the material
regularly to ensure that it is still valid
and current. Broken links are an
indication that a site is not being
updated regularly.

Is the advertising responsible?
Many reputable Internet sites
contain advertising, but beware of
those that allow advertising of products next to news articles about the
product. Also, a reliable site will
clearly differentiate between advertising and medical information. •
For more information, contact
ymr physician or contact the
M. D. Anderson Information Line:

National Library of Medicine: www.nlm.nih.gov
Offers information on clinical trials, allows the user access to abstracts from medical
journals, and provides a directory of health organizations.

({) (800) 392-1611 within
the United States, or

oncology.com: www.oncology.com
Includes information for patients and caregivers.

({) (713) 792-6161 in Houston
and mtside the United States.

Rxlist: www.rxlist.com
Provides information about prescription drugs and drug interactions.
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New DNA Microarray Technology
Could Speed Up Discovery of the
Genetic Causes of Lung Cancer
by Maureen E. Goode, Ph.D.

ith initial
sequendng of
the entire human
genome now
compkte, discovering how
heredity influences health
seems only a step away. Armed
with the human genetic code,
researchers are testing a series of
new technologies such as DNA
microarrays, or "chips, " that
could exponentially speed up
the process of identifying disease genes, enabling researchers
to more easily evaluate individual disease risk based
on the analysis ofseveral
genetic variables.
Changes in some genes have
already been associated with an
increase in cancer risk. But although
some people seem to carry in their
genes an increased risk for can cer,
it is unlikely that any one gene by
itself causes cancer. "Even the highly
penetrant BRCAl and BRCA2 gene
mutations, which have bee n identified as strong components in some
familial breast and ovarian cancers,
are now believed to interact with
other factors to modify the individual
risk of breast and ovarian cancer
among carriers," said Patricia A.
Thompson, Ph.D., an assistant
professor in the Department of
Epidemiology at The University
of Tex as M. D. Anderson Cancer
Center. "Many other genes and the
e nvironment may play a role, too.
Lung cancer is another good example of this. Although smoking
increases the average person's risk,
some people smoke for years without
6 / MD Anderson OncoLog

getting lung cancer, and some nonsmokers get lung cancer. "
Thompson, Margaret Spitz, M.D.,
M.P.H., chairman of the Department
of Epidemiology at M. D. Anderson,
and Michael Hogan, Ph.D., chief
scientific officer of Genometrix, Inc.
and professor of biophysics at Baylor
College of Medicine, are using DNA
microarray technology (see sidebar)
to develop a rapid automated system
for assessing an individual's risk for
lung cancer.
It is a lready possible to d etermine
individual risk for some diseases.
"Cardiovascular disease is a good
example of a multifactorial disease
for which we have identified some of
the contributing factors," Dr. Hogan
explained. "Both clinicians and
patients know that to determine your
risk for cardiovascular disease, you
should be tested for LDL, HDL, and
cholesterol. But we just don't know
that much about the factors that
cause cancer." Some factors may not
have the same effect in each person.
"The body has numerous redundant
capacities to clear the genetic damage that leads to cancer, and when it
doesn't do a good enough job in one
area, it sometimes can in another."
So, the goal of current cancer riskassessment studies is to identify
groups of factors that affect the
probability that a particular cancer
will develop in a person.
Finding these factors is the ratelimiting step in risk assessment. Years
of research by scientists have revealed
about 33 common genetic variants
(carried by more than 2% of the
population) that may be involved
in individual susceptibility to lung
cancer. Some of these genes were
singled out by their known roles in
the metabolism of select therapeutics
and tobacco carcinogens. For instance, people with certain genetic
variants of the enzyme Nacetyltransferase have long been known to be

"slow acetylators," that is, to break
down some drugs and carcinogens
more slowly than other patients do.
The Genometrix microarray platform enables rapid identification of
such patients, who should be given
lower doses of certain drugs and who
may be more sensitive to carcinogens
found in tobacco products.
These gene variants represent
the genetic d iversity in the human
population and are common, unlike
mutations such as BRCAl and BRCA2.
To prove a role for these genes in
disease, scientists need to show that
a gene has an effect in 10,000 to
100,000 people-at least 100 times
the number of people usually studied. Using current techniques to
identify these variants, commonly
referred to as genotyping, these large
studies can take years, but by applying DNA ch ip technology, a miniaturized version of these techniques,
researchers can test blood samples
from 2000 people for the 33 genes
in only two days. This n ew methodology promises to speed up both
identification of new disease gen es
and confirmation of suspect genes.
Dr. Hogan's interest in screening
for genes that cause lung cancer
began in 1997, when h e met Dr.
Spitz, a well-known expert in the
epidemiology of lung cancer, at a
scientific meeting in Liverpool,
England. Dr. Spitz and her colleagues
have shown that patients with lung
cancer have a lower than normal
capacity for repairing the DNA
damage from cigarette smoking that
leads to lung cancer. However, many
genes help repair DNA damage, and
singling out th e ones involved in
lung cancer is a daunting proposition. "I realized from talking to
Dr. Spitz," said Dr. Hogan, "that the
Genomeu·ix automated DNA microarray technology was the way to go
for such large-scale population
studies." Dr. Spitz suggested that Dr.

Many genes help repair DNA
damage, and singling out the
ones involved in lung cancer
is a daunting proposition.
Hogan also speak to Dr. Thompson,
who was then studying genetic
susceptibility to d isease at the National Center for Toxicological
Research. Drs. Thompson and
Hogan began collaborating, and
Dr. Thompson joined the faculty
ofM. D. Anderson in July 1999.
The team's immediate goal is to
validate the microarray by assessing
whether the microarray process and
conventional genotyping produce
the same results in 1000 DNA
samples from healthy individuals and
patients with cancer. If this validation
test is successful, Genometrix will massproduce the optimized chip, and
Drs. Thompson, Hogan, and Spitz
will use it to screen DNA samples
from patients with lung cancer to
determine whether their genes are
different from those of healthy
people. The study will most likely
show that certain gene variants are
more common in, but not exclusive
to, patients ·with lung cancer. These
data, in combination with exposure
data such as whether or not the
person uses tobacco products, will
eventually be used to d etermine the
probability that lung cancer will
develop in a given person.
With these individual risk profiles,
health care practitioners will someday
be able to give patients personalized
instructions on how to reduce their
risk for complex diseases like lung
cancer. For instance, a person with a
mutation in a gene that detoxifies a
particular carcinogen will be told to
avoid that carcinogen,just as now a
person whose parents have heart
disease is told to lower his cholesterol
level. "Th e DNA microarrays," said
Dr. Hogan, "are just a way of taking
a family history in excruciating
detail." •

contact Dr.
Thompson at (713) 795-2492 or
Dr. Spitz at (713) 792-3020.
FOR MORE INFORMATION,

Miaoarrays Reduce Time,
Labor, and Cost of DNA Analysis
by Maureen E. Goode, Ph.D.

D

NA microarrays, which are being developed by several research
groups, are ?1iniaturized forms of current DNA screening procedures,
be_ttered by improved DNA storage, more rapid processing, and
automaaon. In most research laboratories, liquid DNA is isolated from blood
samples and stored in huge freezers. The freezers are expensive and take up a
lot of room, and a power outage that thaws the samples can ruin years of
work. Dr. Hogan and colleagues have circumvented these problems by
developing an automated
Prototype Risk-Tox Microarray
technology for storing
blood samples at room
temperature, spotted on
Antiscnsc
special papers about 5 by 5
r
e WT Var
WT Var •
cm square.
j •• • • • • • • • NAT2 (191)
• • e e NAT2 (282)
Genes in the spotted
e e e e NAT2 (341)
blood samples are ampliNAT2 (481}
•• •• •• •• •• NAT21590)
fied by the polymerase
••• • • • • NAT2 (8S7)
••
chain reaction (PCR), a
•• • • •• .... . .•......• . COMT (SS0)
tech nique commonly
Alignment m.»rkors
used to replicate genes in
vitro. PCR makes a small
DNA sample detectable
by copying a specific gene The DNA chip layoutfor the normal (WT) and
or part of a gene over
mutant (Var) Jorms of six regions of the NAT2
and over until there are
gene and one region of the COMT gene are shown.
enough copies to analyze. The results ofan actual screening are shown in
In PCR, artificial, short
the upper right.
pieces of the gene, called
primers, are added to a DNA sample along with amplifying enzyme.
The standard procedures for analyzing sequences of the resulting
products and determining the presence of variants are numerous and
i?c~ud~ several methods of sequence and fragment analysis. The major
hmttatlons to these existing technologies are the time, labor, and costs
involved in analyzing, at most, five genes simultaneously in a single DNA
sample. In contrast, the Genometrix technology allows the procedure to
be perform~d at room temperature for several hours and can evaluate up
to 50 genes m thousands of samples. The key improvement is the use of
the DNA chip, in_wh ich synthetic DNA segments (probes) that bind up to
50 genes and t~~tr m:i-itants are spotted to form an array within a 4 by 4
mm square of s1hcomzed glass. One such array is formed in each well of a
96-well microtiter plate, to which an individual's PCR-amplified DNA
sample is added. Each amplified gene (or its mutant variant) binds to the
array at the site of its complementary probe, and a fluorescent marker is
incorporated into the bound, amplified DNA. Whether a person has a
normal gene or a mutant one is determined by examining the fluorescent
pattern on the chip, which is detected and analyzed numerically.
Overall, Genometrix's system is 10 times faster than conventional
genotyping methods and is almost completely automated. Ironically,
these advances have created their own problem: they generate more
data points than can be evaluated by conventional data analysis methods.
Information specialists at Genometrix and M. D. Anderson, under the
direction of Dr. Christopher Amos, a professor in the Department of
Epidemiology, are therefore developing new statistical techniques to
handle the large volume of data. •
.A.
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Turning Knowledge Into Effective Gene Therapies
Jack A. Roth, M.D.
Professor, Department
of Thoracic and
Cardiovascular Surgery

Gary L. Clayman, M.D.,
D.D.S.
Associate Professor,
Department of Head
and Neck Surgery

Over th e last 20 years, many of the
mysteries underlying the o rig ins of
cancer have been solved, and a large
bod y of evide nce implicates alte ratio ns
in normal gene .
Oncogenes and tumo r supprc o r
genes arc especially susceptible to
acquiring mutatio ns and deletio ns tha t
pre dispo e a cell to becoming cancerou
Oncogenes become hyperactive whe n
mutated or overcxpre ed. Tumo r
suppressor gene· no rmally functio n to
regulate the cell cycle and repa ir D A
damage, but they are freque ntly inactivated by mutatio ns o r pro mo ter
sile ncing.
The cha lle nge clinicia ns face i to mm
the wealth of in formatio n about gene
into useful the rapies. Their task is made
easier b}' the ad,·,rntage that gene
the rapy offe r : genes arc readily available
and easil)' expre ed , and the effects of
therape utic gene expre io n may be
hig hly c lccti,·c, with a wide tl1erapeutic
window. Fo r exa mple, the p53 tumo r
suppre o r gene, which can cau e
apo ptosis in cancer cells, d oes no t affect
8 I !\10 Anderson Onc oLog

no rmal cells, even whe n ove rexprcssed.
The bigge t proble m facing cancer
gene therapy has been develo ping
vecLOrs that can cffi cie nlly deliver genes
to a sufficient numbe r of cancer cell .
Curre nt vecto rs utilize re u·oviruses a nd
adcnoviruscs that a re rendered re plicatio n-defective and incapable of causing
disease. Despite the ir limitatio ns, in
specific clinical siLUa tio ns these vecto rs
can deliver, by inU"atumoral injection ,
therapeutic genes in sufficie nt quan tities to mediate clinically relevant tumo r
regression.
A rcplication-clcfcctivc ade novirus
expressing the normal p53 gene
(Ad-p53) has been shown to e nhance
local tumor contro l and ensitize
cancer cells to tl1e cytotoxic effects of
chc motllerapy and radjatio n therapr.
In phase I and phase II sllldies, serio us
,•eclor-related advcr e eYents have been
seen in fewer tllan 5% of pa tie nts, and
no vector-related d eatlls have occurred.
At this instiLUtio n, protocols with
i11lratumo1"al injectio n of Ad-p53 are
now e nro lling pa tie n ts with lung, head
and neck, bladde r, and brain cancer .
Re earch in tile fie ld of gene therapy
is moving rapidly, a nd with the completion of the Human Geno me Project,
ide ntificatio n of cancer-re lated genes
will accelerate. Techniques that reveal
tl1e genetic signature of particular
cancers may the n be used to ide ntify
crilical target gene . Already, clinical
trials of vecto r tha t can deli,·er gene
to distant metastatic site will begin
thi year, expanding the u e of gene
the rapy to the treatment of botll local
and metastatic disea e.
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